<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04860713</url>
  </required_header>
  <id_info>
    <org_study_id>2021-02-03-MMC</org_study_id>
    <nct_id>NCT04860713</nct_id>
  </id_info>
  <brief_title>An Efficacy and Safety of Proprietary Formulations of Oral Ketamine + Aspirin in Treatment of Acute</brief_title>
  <official_title>An Efficacy and Safety of Proprietary Formulations of Oral Ketamine + Aspirin and Nurtec (Rimegepant) in Adult Patients Presenting to the ED With Acute Headache: Prospective, Randomized, Open-Label, Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Antonios Likourezos</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Maimonides Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Headaches affect over 50% of patients annually, with close to 4% of ED visits for headache.&#xD;
      Most headaches managed in the ED are benign, with 90% of these headaches classified as&#xD;
      tension, migraine, or cluster. At present, the satisfaction with ED treatment of headache is&#xD;
      low, and despite the multitude of available medications, the evidence- based treatment&#xD;
      options are often quite limited. There are over twenty different types of medications&#xD;
      available to the ED clinicians for managing headache, many with different routes of&#xD;
      administration (parenteral, intranasal, subcutaneous, and oral). Many of these medications&#xD;
      are provided in so-called &quot;headache cocktail&quot;, which varies based on the physician,&#xD;
      institution, and patient preferences.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      STUDY OBJECTIVES: To compare analgesic efficacy and rates of side effects of a proprietary&#xD;
      formulation of orally administered aspirin and ketamine (AOK) to a Nurtec ODT (Rimegepant)&#xD;
      for pain management in adult ED patients presenting to the ED with acute headache.&#xD;
&#xD;
      HYPOTHESIS: We hypothesize that the administration of AOK will provide similar analgesia at&#xD;
      60 minutes post-administration in comparison to Nurtec (Rimegepant) in adult patients&#xD;
      presenting to the ED with acute headache. The primary outcome of this trial is the difference&#xD;
      in participant's pain scores at 60 minutes post-medication administration.&#xD;
&#xD;
      STUDY DESIGN:&#xD;
&#xD;
      Subjects:&#xD;
&#xD;
      Patients 18 years of age and older presenting to the ED with acute headache (defined as HA&#xD;
      lasting no more than 1 week) and an initial pain score of 5 or more on a standard 11- point&#xD;
      (0 to 10) numeric rating scale and requiring oral analgesia as determined by the treating&#xD;
      attending physician. Patients' screening and enrollment will be performed by study&#xD;
      investigators and research assistants. All patients will be enrolled at various times of the&#xD;
      day when study investigators will be available for patient enrollment and an ED pharmacist&#xD;
      will be available for medication preparation.&#xD;
&#xD;
      Design: This is a prospective, randomized, open-label, equivalence trial comparing analgesic&#xD;
      efficacy and safety of AOK and Nurtec (Rimegepant) in patients presenting to the ED of&#xD;
      Maimonides Medical Center with acute headache. Upon meeting the eligibility criteria,&#xD;
      patients will be randomized into one of the two study arms: Group I will receive AOK, and&#xD;
      Group II will receive Nurtec.&#xD;
&#xD;
      Data Collection Procedures: Each patient will be approached by a study investigator for&#xD;
      acquisition of written informed consent and Health Insurance Portability and Accountability&#xD;
      Act authorization after being evaluated by the treating emergency physician and determined to&#xD;
      meet study eligibility criteria. When English will not be the participant's primary language,&#xD;
      a language- appropriate consent form will be used and non-investigator, hospital employed,&#xD;
      trained interpreters or licensed telephone interpreters will assist in acquisition of&#xD;
      informed consent. Baseline pain score will be determined with an 11-point numeric rating&#xD;
      scale (0 to 10), described to the patient as &quot;no pain&quot; being 0 and &quot;the worst pain&#xD;
      imaginable&quot; being 10. A study investigator will record the patient's body weight and baseline&#xD;
      vital signs. All data will be recorded on data collection sheets, including patients' sex,&#xD;
      demographics, medical history, and vital signs, and entered into SPSS (version 24.0; IBM&#xD;
      Corp) by the research manager. Confirmation of written consent acquisition for all&#xD;
      participants, and statistical analyses will be conducted by the statistician, who will work&#xD;
      independently of any data collection.&#xD;
&#xD;
      Expected Outcomes: The primary outcome will include a comparative reduction of pain scores on&#xD;
      numeric rating pain scale (NRS) at 60 minutes from the baseline. The secondary outcomes will&#xD;
      include a need for rescue analgesia, rates of adverse effects and change in pain score up to&#xD;
      120 minutes. With respect to unique adverse effects of ketamine, we will use Side Effect&#xD;
      Rating Scale for Dissociative Anesthetics (SERSDA) and Richmond Agitation Sedation Scale&#xD;
      (RASS) (ref) SERSDA Scale includes fatigue, dizziness, nausea, headache, feeling of&#xD;
      unreality, changes in hearing, mood change, general discomfort, and hallucinations with&#xD;
      severity of each graded by patients on a five-point scale, with &quot;0&quot; representing the absence&#xD;
      of any adverse effects and &quot;4&quot; representing a severely bothersome side effect. RASS evaluates&#xD;
      the severity of agitation and/or sedation in accordance with the nine-point scale with scores&#xD;
      ranging from &quot;-4&quot; (deeply sedated) to &quot;0&quot; (alert and calm) to &quot;+4&quot; (combative).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 22, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Pain score at 60 minutes</measure>
    <time_frame>60 minutes</time_frame>
    <description>Change of pain scores on numeric rating pain scale (NRS) at 60 minutes mark form the baseline. The NRS is an 11 item Likert Scale ranging from 0 (no pain) to 10 (very severe pain) with 5 indicating moderate pain.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>AOK Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Drug: Proprietary oral formulation of 0.85mg/kg of ketamine + 324mg of aspirin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nurtec (Rimegepant) Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Drug: 75 mg of ODT</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>aspirin and ketamine</intervention_name>
    <description>Drug: Proprietary oral formulation of 0.85mg/kg of ketamine + 324mg of aspirin</description>
    <arm_group_label>AOK Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nurtec (Rimegepant)</intervention_name>
    <description>Drug: 75 mg of ODT</description>
    <arm_group_label>Nurtec (Rimegepant) Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients age 18 and older&#xD;
&#xD;
          -  Acute Headache&#xD;
&#xD;
          -  Initial pain score of 5 or more on a standard 11- point (0 to 10) numeric rating&#xD;
             scale.&#xD;
&#xD;
          -  Awake, alert, and oriented to person, place, and time&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  altered mental status,&#xD;
&#xD;
          -  allergy to aspirin, ketamine and rimegepant,&#xD;
&#xD;
          -  pregnancy and breastfeeding&#xD;
&#xD;
          -  unstable vital signs (systolic blood pressure &lt;90 or&gt;180 mm Hg, pulse rate &lt;50 or &gt;150&#xD;
             beats/ min, and respiration rate &lt;10 or &gt;30 breaths/min)&#xD;
&#xD;
          -  inability to provide consent&#xD;
&#xD;
          -  consumption of Aspirin or NSAID's within 6 hours of arrival to the ED or acetaminophen&#xD;
             within 4 hours of arrival&#xD;
&#xD;
          -  active PUD&#xD;
&#xD;
          -  history of GI Hemorrhage&#xD;
&#xD;
          -  history of renal and hepatic insufficiency&#xD;
&#xD;
          -  past medical history of alcohol or drug abuse&#xD;
&#xD;
          -  schizophrenia&#xD;
&#xD;
          -  clinical findings concerning for acute intracranial process, acute infections process&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sergey Motov, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maimonides Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Antonios Likourezos, MA, MPH</last_name>
    <phone>7182836896</phone>
    <email>alikourezos@maimonidesmed.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sergey Motov, MD</last_name>
    <email>smotov@maimonidesmed.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Maimonides Medical Center</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonios Likourezos, MA, MPH</last_name>
      <email>alikourezos@maimonidesmed.org</email>
    </contact>
    <contact_backup>
      <last_name>Sergey Motov, MD</last_name>
      <email>smotov@maimonidesmed.org</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 22, 2021</study_first_submitted>
  <study_first_submitted_qc>April 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 27, 2021</study_first_posted>
  <last_update_submitted>April 26, 2021</last_update_submitted>
  <last_update_submitted_qc>April 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Maimonides Medical Center</investigator_affiliation>
    <investigator_full_name>Antonios Likourezos</investigator_full_name>
    <investigator_title>Research Administration Director</investigator_title>
  </responsible_party>
  <keyword>Emergency Medicine</keyword>
  <keyword>Pain</keyword>
  <keyword>Pain Management</keyword>
  <keyword>Acute Headache</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Ketamine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 23, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/13/NCT04860713/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

